AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
AstraZeneca
AstraZeneca
University of Michigan Rogel Cancer Center
Neonc Technologies, Inc.
AstraZeneca
Ruijin Hospital
Jiangsu HengRui Medicine Co., Ltd.
Daiichi Sankyo